Page last updated: 2024-08-24

topotecan and mitoxantrone

topotecan has been researched along with mitoxantrone in 68 studies

Research

Studies (68)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's6 (8.82)18.2507
2000's41 (60.29)29.6817
2010's21 (30.88)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Imai, Y; Sugimoto, Y; Tsukahara, S; Tsuruo, T; Ueda, K1
Allen, JD; Buitelaar, M; Schinkel, AH; Van Dort, SC; van Tellingen, O1
Gibbons, S; Kaatz, GW; Zloh, M1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL1
Friedrich, TD; Guzzo, PR; Jason Herr, R; Nacro, K; Peace, D; Zha, CC1
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Benfenati, E; Raska, I; Toropov, AA; Toropova, AP1
Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L1
Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M1
Chen, X; Lin, X; Skolnik, S; Wang, J1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR1
Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Cowan, KH; Horton, JK; Schneider, E; Yang, CJ1
Ganapathi, R; Grabowski, D1
Tannock, IF; Vukovic, V1
Allen, JD; Brinkhuis, RF; Schinkel, AH; Wijnholds, J1
de Jong, LA; Floot, BG; Maliepaard, M; Pluim, D; Ruevekamp-Helmers, MC; Schellens, JH; van Gastelen, MA; van Waardenburg, RC1
Bates, SE; Brangi, M; Ciotti, M; Fojo, T; Kohlhagen, G; Litman, T; Nishiyama, K; Pommier, Y; Robey, R; Takimoto, C1
Allen, JD; Dalton, WS; de Jong, MC; Maliepaard, M; Pijnenborg, AC; Ross, DD; Scheffer, GL; Schellens, JH; Scheper, RJ; Schroeijers, AB; van der Kolk, DM; van der Valk, P; van Gastelen, MA1
Beijnen, JH; Brinkhuis, RF; Jonker, JW; Maliepaard, M; Schellens, JH; Schinkel, AH; Smit, JW1
Beijnen, JH; Jonker, JW; Maliepaard, M; Scheffer, GL; Schellens, JH; Scheper, RJ; Schinkel, AH; Smit, JW1
Kancherla, R; Nair, JS; Seiter, K; Traganos, F; Tse-Dinh, YC1
Beggiolin, G; Carenini, N; Carminati, P; De Cesare, M; De Isabella, P; Palumbo, M; Perego, P; Pezzoni, G; Pisano, C; Pratesi, G; Scheffer, GL; Tartaglia, L; Zunino, F1
Bates, SE; Dean, M; Honjo, Y; Hrycyna, CA; Litman, T; Medina-Pérez, WY; Robey, RW; van de Laar, A; Yan, QW1
Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A1
Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Tsuruo, T1
Chen, S; Gomez, SP; Mainwaring, MG; McCarley, D1
Duan, Z; Kronish, KM; Lamendola, DE; Penson, RT; Seiden, MV1
Braylan, R; Chen, SF; Fieniewicz, KJ; Gomez, SP; Kahn, S; Leather, H; Lynch, J; Mainwaring, MG; May, WS; Moreb, J; Reddy, V; Rimsza, LM; Rowe, TC; Weeks, FW; Wingard, JR1
Abbott, BL; Andreeff, M; Barnes, Y; Colapietro, AM; Marini, F; Sorrentino, BP1
Allen, JD; Koomen, GJ; Lakhai, JM; Reid, G; Schellens, JH; Schinkel, AH; van der Valk, M; van Loevezijn, A; van Tellingen, O1
Imai, Y; Ishikawa, E; Kage, K; Miki, Y; Nakane, M; Sugimoto, Y; Tsukahara, S; Tsuruo, T1
Fedier, A; Fink, D; Haller, U; Lenherr, L; Schwarz, VA; Steiner, RA1
Huang, F; Lu, HZ; Wu, DL1
Doi, S; Kamihira, S; Kawabata, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Sugahara, K; Tsurutani, J; Yamada, Y1
Doi, S; Ikegami, Y; Kitazaki, T; Kohno, S; Mizuta, Y; Murase, K; Nakamura, Y; Nakatomi, K; Oka, M; Ross, DD; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Darzynkiewicz, Z; Holden, E; Huang, X; Luther, E; Okafuji, M; Traganos, F1
Bolaños-Meade, J; Gojo, I; Guo, C; Karp, JE1
Beck, WT; Ee, PL; He, X; Ross, DD1
Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M1
Coburn, RA; Morris, ME; Wang, Q; Yang, X; Zhou, XF1
Dai, W; Darzynkiewicz, Z; Halicka, HD; Huang, X; Kurose, A; Tanaka, T; Traganos, F1
Dai, Y; Gupta, A; Hebert, MF; Mao, Q; Ross, DD; Thummel, KE; Unadkat, JD; Vethanayagam, RR1
Dai, W; Darzynkiewicz, Z; Huang, X; Kurose, A; Tanaka, T; Traganos, F1
Banerji, S; Los, M1
Beijnen, JH; Borst, P; Breedveld, P; Cipriani, G; Dahlhaus, F; de Wolf, CJ; Jansen, G; Kuil, A; Pluim, D; Scheffer, GL; Schellens, JH; van Eijndhoven, MA1
AFlint, JA; Ardelt, B; Coradetti, T; Darzynkiewicz, Z; Davidowitz, H; Huang, Z; Lin, X; Mandecki, W; MKopacka, WM; Wang, Z1
Allen, JD; Arnold, JC; Holland, ML; Lau, DT1
Darzynkiewicz, Z; Traganos, F; Zhao, H2
Enomoto, T; Hayashi, K; Iizuka, M; Kuranami, M; Nakakuma, T; Sengoku, N; Watanabe, M; Yoshimura, N1
Karp, J1
Dudgeon, DD; Giuliano, KA; Johnston, PA; Lazo, JS; Shinde, SN; Shun, TY; Strock, CJ; Taylor, DL1
Darzynkiewicz, Z; Dobrucki, J; Rybak, P; Traganos, F; Zhao, H1
Deng, Y; Ma, Y; Wang, L; Yang, Q; Zhao, Y; Zhou, X1
Fu, LW; Liang, YJ; Su, XD; Wang, F; Wu, XP1
Ambudkar, SV; Baer, MR; Bhullar, J; Cai, L; Chen, ZS; Fang, HB; Natarajan, K; Sen, R; Shukla, S1
Patel, KJ; Tannock, IF; Trédan, O1
Audisio, E; Boccadoro, M; Bruno, B; Crisà, E; Ferrero, D; Festuccia, M; Frairia, C; Gatti, T; Giai, V; Marmont, F; Passera, R; Riera, L1
Chen, L; Chen, Z; Fu, L; Li, F; Wang, F; Wang, X; Zhang, W1
Barbuti, AM; Chen, ZS; Wang, YJ; Wen, AW; Wurpel, JND; Yu, XY; Zhang, GN; Zhang, YK; Zhu, XJ1
Jiang, S; Lan, S; Ma, D; Mao, D; Shi, K; Yang, X1
Altman, JK; Broun, ER; Carroll, MP; Karp, JE; Kaufmann, SH; Ketterling, RP; Lazarus, HM; Litzow, MR; Luger, SM; Paietta, EM; Pratz, KW; Rowe, JM; Rybka, WB; Tallman, MS; Tun, HW; Wang, XV; Zhang, Y1
Al-Rihani, SB; Ambudkar, SV; Chen, ZS; Kaddoumi, A; Lei, ZN; Shi, Z; Shukla, S; Wang, DS; Wang, YJ; Zhang, GN; Zhang, XY; Zhang, YK1
Cannon, RE; Perera, L; Sinha, BK1

Reviews

4 review(s) available for topotecan and mitoxantrone

ArticleYear
Membrane transporters in drug development.
    Nature reviews. Drug discovery, 2010, Volume: 9, Issue:3

    Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs

2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
    Bone marrow transplantation, 2001, Volume: 28, Issue:7

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation

2001
[Drug-resistant proteins in breast cancer: recent progress in multidrug resistance].
    Ai zheng = Aizheng = Chinese journal of cancer, 2003, Volume: 22, Issue:4

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitoxantrone; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured

2003

Trials

4 trial(s) available for topotecan and mitoxantrone

ArticleYear
Treatment of refractory acute leukemia with timed sequential chemotherapy using topotecan followed by etoposide + mitoxantrone (T-EM) and correlation with topoisomerase II levels.
    Leukemia & lymphoma, 2002, Volume: 43, Issue:5

    Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; DNA Fragmentation; DNA Topoisomerases, Type II; Enzyme Induction; Etoposide; Female; Humans; Leukemia; Male; Middle Aged; Mitoxantrone; Topotecan

2002
A phase II study of timed sequential therapy of acute myelogenous leukemia (AML) for patients over the age of 60: two cycle timed sequential therapy with topotecan, ara-C and mitoxantrone in adults with poor-risk AML.
    Leukemia research, 2004, Volume: 28, Issue:6

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Demography; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Remission Induction; Risk Factors; Survival Rate; Topotecan; Treatment Outcome

2004
Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
    Annals of hematology, 2014, Volume: 93, Issue:8

    Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Consolidation Chemotherapy; Cytarabine; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Maintenance Chemotherapy; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Neoplasm, Residual; Prognosis; Proportional Hazards Models; Remission Induction; Risk; Survival Analysis; Topotecan; Transplantation, Autologous; Treatment Outcome; Vidarabine

2014
A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.
    American journal of hematology, 2019, Volume: 94, Issue:1

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cytarabine; Disease-Free Survival; Etoposide; Female; Flavonoids; Follow-Up Studies; Gastrointestinal Diseases; Hematologic Diseases; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Piperidines; Recurrence; Remission Induction; Salvage Therapy; Sirolimus; Topotecan; Tumor Lysis Syndrome

2019

Other Studies

60 other study(ies) available for topotecan and mitoxantrone

ArticleYear
Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists.
    Molecular cancer therapeutics, 2003, Volume: 2, Issue:1

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Survival; Diethylstilbestrol; Drug Resistance, Neoplasm; Estrogen Antagonists; Estrogens; Estrone; Female; Humans; K562 Cells; Kinetics; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Tamoxifen; Topotecan; Tumor Cells, Cultured

2003
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Cancer research, 2003, Mar-15, Volume: 63, Issue:6

    Topics: Animals; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Biological Transport; Cell Line; Dogs; Drug Resistance, Neoplasm; Etoposide; Male; Mice; Mice, Knockout; Neoplasm Proteins

2003
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
    Bioorganic & medicinal chemistry letters, 2004, Feb-23, Volume: 14, Issue:4

    Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular

2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
    Current drug discovery technologies, 2004, Volume: 1, Issue:4

    Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration

2004
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
    Bioorganic & medicinal chemistry, 2007, Jun-15, Volume: 15, Issue:12

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Enzyme Inhibitors; Humans; Magnetic Resonance Spectroscopy; Pyrroles; Quinones; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors

2007
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:4

    Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water

2010
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:11

    Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity

2010
Attenuation of intestinal absorption by major efflux transporters: quantitative tools and strategies using a Caco-2 model.
    Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:2

    Topics: Adenosine; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Caco-2 Cells; Chromatography, Liquid; Dibenzocycloheptenes; Diketopiperazines; Drug Discovery; Heterocyclic Compounds, 4 or More Rings; Humans; Intestinal Absorption; Mass Spectrometry; Models, Biological; Neoplasm Proteins; Pharmaceutical Preparations; Predictive Value of Tests; Propionates; Quinolines; Substrate Specificity

2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
    Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10

    Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection

2012
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
    Journal of medicinal chemistry, 2013, Feb-14, Volume: 56, Issue:3

    Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs

2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
    Cancer research, 1995, Sep-15, Volume: 55, Issue:18

    Topics: Antineoplastic Agents; Breast Neoplasms; Camptothecin; Cell Survival; DNA Topoisomerases, Type I; Drug Resistance; Female; Humans; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

1995
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
    Annals of the New York Academy of Sciences, 1996, Dec-13, Volume: 803

    Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Drug Resistance, Multiple; Drug Synergism; Enzyme Inhibitors; Etoposide; Leukemia L1210; Mice; Mitoxantrone; Topoisomerase I Inhibitors; Topotecan

1996
Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan.
    British journal of cancer, 1997, Volume: 75, Issue:8

    Topics: Animals; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Survival; DNA, Neoplasm; Female; Humans; Hydrogen-Ion Concentration; Mammary Neoplasms, Experimental; Mice; Mitoxantrone; Paclitaxel; Topotecan; Tumor Cells, Cultured; Urinary Bladder Neoplasms

1997
The mouse Bcrp1/Mxr/Abcp gene: amplification and overexpression in cell lines selected for resistance to topotecan, mitoxantrone, or doxorubicin.
    Cancer research, 1999, Sep-01, Volume: 59, Issue:17

    Topics: 3T3 Cells; Amino Acid Sequence; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; DNA, Complementary; Doxorubicin; Drug Resistance, Neoplasm; Gene Amplification; Mice; Mitoxantrone; Molecular Sequence Data; RNA, Messenger; Topotecan

1999
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
    Cancer research, 1999, Sep-15, Volume: 59, Issue:18

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Drug Resistance, Multiple; Female; Gene Expression Regulation, Neoplastic; Humans; Irinotecan; Kinetics; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured

1999
Camptothecin resistance: role of the ATP-binding cassette (ABC), mitoxantrone-resistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells.
    Cancer research, 1999, Dec-01, Volume: 59, Issue:23

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Cell Survival; DNA Damage; Drug Resistance, Multiple; Epirubicin; Female; Glucuronides; Glucuronosyltransferase; Humans; Irinotecan; Microscopy, Confocal; Mitoxantrone; Polymerase Chain Reaction; Topotecan; Tumor Cells, Cultured

1999
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines.
    Cancer research, 2000, May-15, Volume: 60, Issue:10

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Topotecan; Tumor Cells, Cultured

2000
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
    Journal of the National Cancer Institute, 2000, Oct-18, Volume: 92, Issue:20

    Topics: Acridines; Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; DNA, Complementary; Enzyme Inhibitors; Female; Fetus; Humans; Intestinal Absorption; Isoquinolines; Male; Mice; Mitoxantrone; Neoplasm Proteins; Placenta; Pregnancy; RNA, Messenger; Tetrahydroisoquinolines; Topotecan

2000
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mitoxantrone; Neoplasm Proteins; Ovarian Neoplasms; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2000
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
    Annals of the New York Academy of Sciences, 2000, Volume: 922

    Topics: Acute Disease; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cytarabine; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Enzyme Inhibitors; Etoposide; Humans; Isoenzymes; Leukemia; Leukocytes; Lymphoma, Non-Hodgkin; Mitoxantrone; Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

2000
A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone-selected colon carcinoma cell line.
    Cancer research, 2001, Aug-15, Volume: 61, Issue:16

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; DNA Damage; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression; HT29 Cells; Humans; Mice; Mice, Nude; Mitoxantrone; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Topotecan; Xenograft Model Antitumor Assays

2001
Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells.
    Cancer research, 2001, Sep-15, Volume: 61, Issue:18

    Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Genes, MDR; Genetic Vectors; HeLa Cells; Humans; Irinotecan; Mitoxantrone; Mutation; Neoplasm Proteins; Rhodamine 123; RNA, Messenger; Substrate Specificity; Topotecan; Transfection; Tumor Cells, Cultured; Vaccinia virus

2001
Estrone and 17beta-estradiol reverse breast cancer resistance protein-mediated multidrug resistance.
    Japanese journal of cancer research : Gann, 2002, Volume: 93, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Estradiol; Estrone; Female; Flow Cytometry; Humans; Irinotecan; K562 Cells; Mitoxantrone; Neoplasm Proteins; Topoisomerase I Inhibitors; Topotecan; Transfection

2002
Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
    Cancer chemotherapy and pharmacology, 2002, Volume: 49, Issue:5

    Topics: Antigens, Neoplasm; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Nucleus; Cell Survival; Comet Assay; DNA Topoisomerases, Type II; DNA-Binding Proteins; DNA, Neoplasm; Etoposide; Fluorescent Antibody Technique; Humans; K562 Cells; Microscopy, Confocal; Mitoxantrone; Topotecan

2002
Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells.
    Cytokine, 2002, Mar-07, Volume: 17, Issue:5

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Northern; Blotting, Western; Caspase 3; Caspases; Cell Division; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme-Linked Immunosorbent Assay; Genetic Vectors; Humans; Interleukin-6; Interleukin-8; Mitoxantrone; Osteosarcoma; Paclitaxel; Phenotype; RNA; Tetrazolium Salts; Thiazoles; Time Factors; Topotecan; Transfection; Tumor Cells, Cultured

2002
Low levels of ABCG2 expression in adult AML blast samples.
    Blood, 2002, Dec-15, Volume: 100, Issue:13

    Topics: Acute Disease; Adult; Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Cells; Bone Marrow Cells; Drug Resistance, Neoplasm; Female; Fetal Blood; Gene Expression Regulation, Leukemic; Hematopoietic Stem Cells; Humans; Idarubicin; Infant, Newborn; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Neoplasm Proteins; Neoplastic Stem Cells; RNA, Messenger; RNA, Neoplasm; Topotecan

2002
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:6

    Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; In Vitro Techniques; Indoles; Intestines; Mice; Mitoxantrone; Mycotoxins; Neoplasm Proteins; Topotecan; Transfection; Tumor Cells, Cultured; Vincristine

2002
C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Molecular cancer therapeutics, 2002, Volume: 1, Issue:8

    Topics: Alternative Splicing; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Blotting, Northern; Blotting, Western; Camptothecin; DNA, Complementary; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Heterozygote; Homozygote; Irinotecan; Mice; Mitoxantrone; Molecular Sequence Data; Mutation; Neoplasm Proteins; Polymorphism, Genetic; RNA, Messenger; Sequence Analysis, DNA; Topotecan; Transfection; Tumor Cells, Cultured

2002
The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cells.
    International journal of oncology, 2003, Volume: 22, Issue:5

    Topics: Animals; Antineoplastic Agents; BRCA1 Protein; Busulfan; Camptothecin; Cell Division; Cell Line; Doxorubicin; Etoposide; Fibroblasts; Gene Deletion; Genes, BRCA1; Mice; Mitoxantrone; Topotecan; Tumor Suppressor Protein p53

2003
Expression and functional analyses of breast cancer resistance protein in lung cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-01, Volume: 9, Issue:8

    Topics: Antineoplastic Agents, Phytogenic; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Transport; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan

2003
Reversal of breast cancer resistance protein (BCRP/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic.
    International journal of cancer, 2004, Jan-01, Volume: 108, Issue:1

    Topics: Aminocoumarins; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Camptothecin; Coumarins; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Novobiocin; Topoisomerase I Inhibitors; Topotecan; Tumor Cells, Cultured

2004
Assessment of histone H2AX phosphorylation induced by DNA topoisomerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2004, Volume: 58, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Caspase Inhibitors; Caspases; Cell Cycle; Chromatin Assembly and Disassembly; Cisplatin; Cross-Linking Reagents; DNA; Enzyme Activation; Histones; HL-60 Cells; Humans; Mitoxantrone; Phosphorylation; Protein Binding; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan

2004
Modulation of breast cancer resistance protein (BCRP/ABCG2) gene expression using RNA interference.
    Molecular cancer therapeutics, 2004, Volume: 3, Issue:12

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cells; Choriocarcinoma; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Estradiol; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Mitoxantrone; Neoplasm Proteins; Pregnancy; RNA Interference; RNA, Messenger; Topotecan; Tumor Cells, Cultured; Uterine Neoplasms

2004
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Cancer research, 2005, Feb-15, Volume: 65, Issue:4

    Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan

2005
Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
    Drug metabolism and disposition: the biological fate of chemicals, 2005, Volume: 33, Issue:8

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cell Survival; Dihydropyridines; Drug Interactions; Drug Resistance, Multiple; Female; Humans; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Pyridines; Rats; Rats, Sprague-Dawley; Topotecan

2005
Assessment of ATM phosphorylation on Ser-1981 induced by DNA topoisomerase I and II inhibitors in relation to Ser-139-histone H2AX phosphorylation, cell cycle phase, and apoptosis.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2005, Volume: 68, Issue:1

    Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle; Cell Cycle Proteins; Cell Nucleus; Cytoplasm; DNA-Binding Proteins; Flow Cytometry; Histones; HL-60 Cells; Humans; Immunohistochemistry; Interphase; Kinetics; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors; Topotecan; Tumor Suppressor Proteins

2005
Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
    Cancer chemotherapy and pharmacology, 2006, Volume: 58, Issue:3

    Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cyclosporine; Drug Resistance, Neoplasm; Female; Flow Cytometry; Humans; Immunosuppressive Agents; Mitoxantrone; Neoplasm Proteins; Sirolimus; Substrate Specificity; Tacrolimus; Topotecan

2006
Activation of ATM and histone H2AX phosphorylation induced by mitoxantrone but not by topotecan is prevented by the antioxidant N-acetyl-L-cysteine.
    Cancer biology & therapy, 2006, Volume: 5, Issue:8

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Apoptosis; Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Flow Cytometry; Fluorescent Antibody Technique; Histones; HL-60 Cells; Humans; Lung Neoplasms; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins

2006
Important differences between topoisomerase-I and -II targeting agents.
    Cancer biology & therapy, 2006, Volume: 5, Issue:8

    Topics: Acetylcysteine; Antineoplastic Agents; Antioxidants; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; DNA-Binding Proteins; Histones; Humans; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Cells, Cultured; Tumor Suppressor Proteins

2006
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
    Molecular pharmacology, 2007, Volume: 71, Issue:1

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Breast Neoplasms; Cell Line; Cell Line, Tumor; Dogs; Female; Folic Acid; Humans; Hydrogen-Ion Concentration; Kinetics; Liver; Methotrexate; Mitoxantrone; Neoplasm Proteins; Rabbits; Resveratrol; Stilbenes; Topotecan

2007
Microtransponders, the miniature RFID electronic chips, as platforms for cell growth in cytotoxicity assays.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2006, Nov-01, Volume: 69, Issue:11

    Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Transitional Cell; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Cost Control; Drug Screening Assays, Antitumor; Electronics; Humans; Lab-On-A-Chip Devices; Laser Scanning Cytometry; Lung Neoplasms; Microchip Analytical Procedures; Microscopy, Fluorescence; Mitoxantrone; Radio Waves; Ribonucleases; Topotecan

2006
The multidrug transporter ABCG2 (BCRP) is inhibited by plant-derived cannabinoids.
    British journal of pharmacology, 2007, Volume: 152, Issue:5

    Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cannabinoids; Cell Line; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Dronabinol; Flow Cytometry; Humans; Immunoblotting; Inhibitory Concentration 50; Mice; Mitoxantrone; Neoplasm Proteins; Plant Extracts; Receptor, Cannabinoid, CB1; Reverse Transcriptase Polymerase Chain Reaction; Sulfasalazine; Topotecan; TRPV Cation Channels

2007
Kinetics of histone H2AX phosphorylation and Chk2 activation in A549 cells treated with topotecan and mitoxantrone in relation to the cell cycle phase.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2008, Volume: 73, Issue:6

    Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Checkpoint Kinase 2; DNA Damage; Enzyme Activation; Histones; Humans; Immunohistochemistry; Kinetics; Microscopy, Confocal; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Topotecan

2008
Phosphorylation of p53 on Ser15 during cell cycle caused by Topo I and Topo II inhibitors in relation to ATM and Chk2 activation.
    Cell cycle (Georgetown, Tex.), 2008, Volume: 7, Issue:19

    Topics: Ataxia Telangiectasia Mutated Proteins; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Checkpoint Kinase 2; DNA Damage; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enzyme Inhibitors; Fluorescent Antibody Technique; Humans; Mitoxantrone; Phosphorylation; Protein Serine-Threonine Kinases; Serine; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topotecan; Tumor Suppressor Protein p53; Tumor Suppressor Proteins

2008
[A case of stage IV breast cancer in which a long-term no change state (NC) was attained by a combination of S-1 and TAM following AC-T as a primary systemic therapy (PST)].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2008, Volume: 35, Issue:12

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Drug Combinations; Female; Humans; Mitoxantrone; Neoplasm Staging; Oxonic Acid; Paclitaxel; Tegafur; Time Factors; Tomography, X-Ray Computed; Topotecan

2008
Future research directions for the treatment of AML.
    Clinical advances in hematology & oncology : H&O, 2008, Volume: 6, Issue:11

    Topics: Antineoplastic Agents; Azacitidine; Biomedical Research; Carbazoles; Carboplatin; Cytarabine; Daunorubicin; Decitabine; Enzyme Inhibitors; Etoposide; Flavonoids; Furans; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Piperidines; Quinolones; Staurosporine; Topotecan; Tretinoin

2008
Characterization and optimization of a novel protein-protein interaction biosensor high-content screening assay to identify disruptors of the interactions between p53 and hDM2.
    Assay and drug development technologies, 2010, Volume: 8, Issue:4

    Topics: Antineoplastic Agents; Biosensing Techniques; Camptothecin; Cell Line, Tumor; Checkpoint Kinase 2; Ellipticines; Genes, p53; High-Throughput Screening Assays; Humans; Imidazoles; Mitoxantrone; Piperazines; Protein Binding; Protein Interaction Mapping; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-mdm2; Recombinant Fusion Proteins; Small Molecule Libraries; Spectrometry, Fluorescence; Topotecan; Tumor Suppressor Protein p53

2010
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
    Cytometry. Part A : the journal of the International Society for Analytical Cytology, 2012, Volume: 81, Issue:1

    Topics: Camptothecin; Cell Line, Tumor; DNA Damage; DNA Replication; Etoposide; Histones; Humans; Mitoxantrone; Phosphorylation; Signal Transduction; Topoisomerase Inhibitors; Topotecan

2012
Repeated injections of PEGylated liposomal topotecan induces accelerated blood clearance phenomenon in rats.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2012, Apr-11, Volume: 45, Issue:5

    Topics: Animals; Doxorubicin; Immunoglobulin M; Liposomes; Male; Metabolic Clearance Rate; Mitoxantrone; Phospholipids; Polyethylene Glycols; Rats; Rats, Wistar; Topotecan

2012
ABCG2-overexpressing S1-M1-80 cell xenografts in nude mice keep original biochemistry and cell biological properties.
    Chinese journal of cancer, 2012, Volume: 31, Issue:3

    Topics: Adenosine; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Colonic Neoplasms; Diketopiperazines; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 4 or More Rings; Humans; Inhibitory Concentration 50; KB Cells; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Rhodamine 123; Topotecan

2012
The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:9

    Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carbocyanines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Chlorophyll; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; fms-Like Tyrosine Kinase 3; Fusion Proteins, bcr-abl; Humans; Imidazoles; Inhibitory Concentration 50; Mitoxantrone; Neoplasm Proteins; Protein Binding; Pyridazines; Rhodamine 123; Topotecan

2012
Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues.
    Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:1

    Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Line, Tumor; Coronary Vessels; Doxorubicin; Female; Humans; Kidney; Liver; Mice; Mice, Nude; Mitoxantrone; Myocardium; Neoplasms; Neovascularization, Pathologic; Tissue Distribution; Topoisomerase I Inhibitors; Topotecan; Xenograft Model Antitumor Assays

2013
ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics.
    Scientific reports, 2017, 01-06, Volume: 7

    Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Heterografts; Lapatinib; Mice, Nude; Mitoxantrone; Neoplasm Proteins; Neoplasm Transplantation; Quinazolines; Topotecan

2017
Modulating the function of ATP-binding cassette subfamily G member 2 (ABCG2) with inhibitor cabozantinib.
    Pharmacological research, 2017, Volume: 119

    Topics: Anilides; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Cell Line, Tumor; Drug Resistance, Neoplasm; HEK293 Cells; Humans; Mitoxantrone; Molecular Docking Simulation; Neoplasms; Pyridines; Topoisomerase I Inhibitors; Topotecan

2017
Pro-guest and acyclic cucurbit[n]uril conjugated polymers for the controlled release of anti-tumor drugs.
    Chemical communications (Cambridge, England), 2018, Aug-21, Volume: 54, Issue:68

    Topics: Antineoplastic Agents; Berberine; Bridged-Ring Compounds; Camptothecin; Doxorubicin; Drug Carriers; Drug Liberation; Fluorescent Dyes; HeLa Cells; Humans; Hydrogen-Ion Concentration; Imidazoles; Irinotecan; Mitoxantrone; Polymers; Topotecan

2018
Regorafenib antagonizes BCRP-mediated multidrug resistance in colon cancer.
    Cancer letters, 2019, 02-01, Volume: 442

    Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Binding Sites; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Humans; Male; Mice, Nude; Mitoxantrone; Molecular Docking Simulation; Molecular Dynamics Simulation; Neoplasm Proteins; Phenylurea Compounds; Protein Binding; Protein Conformation; Pyridines; Topotecan; Tumor Burden; Xenograft Model Antitumor Assays

2019
Reversal of drug resistance by JS-K and nitric oxide in ABCB1- and ABCG2-expressing multi-drug resistant human tumor cells.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2019, Volume: 120

    Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Azo Compounds; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Mitoxantrone; Molecular Docking Simulation; Molecular Structure; Nitric Oxide; Nitroso Compounds; Piperazines; Topotecan

2019